Neoadjuvant Chemotherapy Does Not Improve Survival in cT2N0M0 Gastric Adenocarcinoma Patients: A Multicenter Propensity Score Analysis.

Détails

ID Serval
serval:BIB_B783B53575E1
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Neoadjuvant Chemotherapy Does Not Improve Survival in cT2N0M0 Gastric Adenocarcinoma Patients: A Multicenter Propensity Score Analysis.
Périodique
Annals of surgical oncology
Auteur⸱e⸱s
Abboretti F., Lambert C., Schäfer M., Pereira B., Le Roy B., Mège D., Piessen G., Gagnière J., Gronnier C., Mantziari S.
Collaborateur⸱rice⸱s
ADENOKGAST Study Group, AFC-French Association of Surgery
ISSN
1534-4681 (Electronic)
ISSN-L
1068-9265
Statut éditorial
Publié
Date de publication
08/2024
Peer-reviewed
Oui
Volume
31
Numéro
8
Pages
5273-5282
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Résumé
According to current international guidelines, stage cT2N0M0 gastric adenocarcinoma warrants preoperative chemotherapy followed by surgery. However, upfront surgery is often preferred in clinical practice, depending on patient clinical status and local treatment preferences.
The aim of the present study was to assess the impact of neoadjuvant chemotherapy in overall survival (OS) and disease-free survival (DFS) of cT2N0M0 patients.
A retrospective analysis was performed among 32 centers, including gastric adenocarcinoma patients operated between January 2007 and December 2017. Patients with cT2N0M0 stage were divided into upfront surgery (S) and neoadjuvant chemotherapy followed by surgery (CS) groups. Inverse probability of treatment weighting (IPTW) was used to compensate for baseline differences between the groups.
Among the 202 patients diagnosed with cT2N0M0 stage, 68 (33.7%) were in the CS group and 134 (66.3%) were in the S group. CS patients were younger (mean age 62.7 ± 12.8 vs. 69.8 ± 12.1 years for S patients; p < 0.001) and had a better health status (World Health Organization performance status = 0 in 60.3% of CS patients vs. 34.5% of S patients; p = 0.006). During follow-up, recurrence occurred in 27.2% and 19.6% of CS and S patients, respectively, after IPTW (p = 0.32). Five-year OS was similar between CS and S patients (78.9% vs. 68.3%; p = 0.42), as was 5-year DFS (70.4% vs. 68.5%; p = 0.96). Neoadjuvant chemotherapy was associated with neither OS nor DFS in multivariable analysis after IPTW.
Patients with cT2N0M0 gastric adenocarcinoma did not present a survival or recurrence benefit if treated with perioperative chemotherapy followed by surgery as opposed to surgery alone.
Mots-clé
Humans, Stomach Neoplasms/pathology, Stomach Neoplasms/mortality, Stomach Neoplasms/drug therapy, Stomach Neoplasms/surgery, Male, Female, Neoadjuvant Therapy/mortality, Adenocarcinoma/mortality, Adenocarcinoma/pathology, Adenocarcinoma/drug therapy, Adenocarcinoma/surgery, Adenocarcinoma/therapy, Middle Aged, Retrospective Studies, Aged, Survival Rate, Follow-Up Studies, Propensity Score, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Chemotherapy, Adjuvant/mortality, Prognosis, Neoplasm Staging, Gastrectomy/mortality, Neoadjuvant therapy, Propensity score, Stomach neoplasms, Survival analysis
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/05/2024 8:46
Dernière modification de la notice
16/07/2024 6:09
Données d'usage